Evidence map›Paper›PMID 31218570›Full record

ArticleInflammopharmacology2020

Protective anti-inflammatory activity of tovophyllin A against acute lung injury and its potential cytotoxicity to epithelial lung and breast carcinomas.

Dina S El-Agamy, Gamal A Mohamed, Nishat Ahmed, Mohamed A Elkablawy, Mahmoud A Elfaky, Wael M Elsaed, Shaimaa G A Mohamed, Sabrin R M Ibrahim

Abstract read
PubMed Publisher
In one paragraph

Article in Inflammopharmacology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
3.2field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 16 citations in OpenAlex.

  1. Modulation of NF-κB and cytokine signaling byFrontiers in pharmacology · 2026
    Article
  2. The synergistic pathogenic mechanism ofJournal of medical microbiology · 2025
    Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Plants (Basel, Switzerland) · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 2 countries.

Dina S El-AgamyDepartment of Pharmacology and Toxicology, College of Pharmacy, Taibah University, University Street, Al-Madinah Al-Munawwarah, 30078, Saudi Arabia.
Gamal A MohamedDepartment of Natural Products and Alternative Medicine, Faculty of Pharmacy, King Abdulaziz University, Jeddah, 21589, Saudi Arabia.
Nishat AhmedDepartment of Pharmacology and Toxicology, College of Pharmacy, Taibah University, University Street, Al-Madinah Al-Munawwarah, 30078, Saudi Arabia.
Mohamed A ElkablawyDepartment of Pathology, College of Medicine, Taibah University, University Street, Al-Madinah Al-Munawwarah, 30078, Saudi Arabia.
Mahmoud A ElfakyDepartment of Natural Products and Alternative Medicine, Faculty of Pharmacy, King Abdulaziz University, Jeddah, 21589, Saudi Arabia.
Wael M ElsaedDepartment of Anatomy and Embryology, College of Medicine, Taibah University, University Street, Al-Madinah Al-Munawwarah, 30078, Saudi Arabia.
Shaimaa G A MohamedFaculty of Dentistry, British University, El Sherouk City, Suez Desert Road, Cairo, 11837, Egypt.
Sabrin R M IbrahimDepartment of Pharmacognosy and Pharmaceutical Chemistry, College of Pharmacy, Taibah University, University Street, Al Madinah Al-Munawwarah, 30078, Saudi Arabia. sribrahim@taibahu.edu.sa.ORCID http://orcid.org/0000-0002-6858-7560
Taibah University · SAMansoura University · EGAl-Azhar University · EGBritish University in Egypt · EGKing Abdulaziz University · SA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tovophyllin A (TA) is a xanthone isolated from Garcinia mangostana L. (GM, Guttiferae) pericarps that possesses various beneficial bioactivities. However, its protective effects on acute lung injury (ALI) and lung carcinoma have not yet been explored. The current work was designed to investigate the protective potential of TA against ALI and explore the possible mechanism of action. Two different doses of TA were tested against lipopolysaccharide (LPS)-induced ALI in mice. Moreover, the cytotoxic potential of TA was assessed in epithelial lung (A549 cells) and breast (MCF7 cells) carcinomas utilizing a sulforhodamine B (SRB) assay. The results revealed that TA possessed the ability to protect against LPS-induced acute lung damage. TA attenuated LPS-induced pulmonary edema, as it lowered the protein content in the bronchoalveolar lavage fluid (BALF) and the lung W/D ratio. In addition, TA counteracted inflammatory cell infiltration into the lung tissue, as shown by the total and differential cell counts in the BALF and histopathological examination of the lungs. The oxidative burden in the pulmonary tissue was ameliorated in TA-treated animals as there were reductions in the malondialdehyde (MDA) and 4-hydroxynonenal (4-HNE) levels in the lung tissue. TA increased the levels of antioxidants such as reduced glutathione (GSH) and superoxide dismutase (SOD) in the lungs. Furthermore, TA inhibited the activation of nuclear factor-κB (NF-κB). In addition, TA had potent anti-inflammatory activity as it reduced the immunoexpression and levels of the pro-inflammatory cytokines tumor necrosis factor-α (TNF-α), interleukin (IL)-1β and IL-6. Furthermore, TA showed significantly enhanced cytotoxic activity against the MCF-7 and A549 cell lines with IC

Indexed as

A549 CellsAcute Lung InjuryAnimalsAnti-Inflammatory AgentsAntioxidantsBreast NeoplasmsCell Line, TumorCytokinesFemaleHumansInflammationInterleukin-1betaInterleukin-6LungMaleMalondialdehydeAnti-Inflammatory AgentsAntioxidantsCytokinesInterleukin-1betaInterleukin-6MalondialdehydeNF-kappa BProtective AgentsSuperoxide DismutaseTumor Necrosis Factor-alphaxanthoneXanthonesCytokinesCytotoxic activityGarcinia mangostanaInflammationNF-κBPulmonary injuryTovophyllin A

Identifiers

PMID31218570
OpenAlexW2951609326

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.